[go: up one dir, main page]

MA43773B1 - Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée - Google Patents

Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée

Info

Publication number
MA43773B1
MA43773B1 MA43773A MA43773A MA43773B1 MA 43773 B1 MA43773 B1 MA 43773B1 MA 43773 A MA43773 A MA 43773A MA 43773 A MA43773 A MA 43773A MA 43773 B1 MA43773 B1 MA 43773B1
Authority
MA
Morocco
Prior art keywords
fcrn binding
altered fcrn
engineered immunoglobulins
altered
immunoglobulins
Prior art date
Application number
MA43773A
Other languages
English (en)
Other versions
MA43773A (fr
Inventor
Stian FOSS
Jan Terje ANDERSEN
Inger Sandlie
Original Assignee
Universitetet I Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitetet I Oslo filed Critical Universitetet I Oslo
Publication of MA43773A publication Critical patent/MA43773A/fr
Publication of MA43773B1 publication Critical patent/MA43773B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions et des méthodes destinées à une thérapie médiée par des anticorps. En particulier, l'invention concerne des immunoglobulines génétiquement modifiées ayant une demi-vie altérée.
MA43773A 2016-03-14 2017-03-14 Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée MA43773B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307686P 2016-03-14 2016-03-14
EP17717856.3A EP3430039B1 (fr) 2016-03-14 2017-03-14 Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
PCT/IB2017/000327 WO2017158426A1 (fr) 2016-03-14 2017-03-14 Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée

Publications (2)

Publication Number Publication Date
MA43773A MA43773A (fr) 2018-11-28
MA43773B1 true MA43773B1 (fr) 2026-01-30

Family

ID=58548768

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43773A MA43773B1 (fr) 2016-03-14 2017-03-14 Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée

Country Status (27)

Country Link
US (2) US11319383B2 (fr)
EP (2) EP4659813A2 (fr)
JP (2) JP7155008B2 (fr)
KR (3) KR20180127320A (fr)
CN (3) CN109071631B (fr)
AU (1) AU2017232546B2 (fr)
BR (1) BR112018067897A2 (fr)
CA (1) CA3011887C (fr)
CL (1) CL2018002639A1 (fr)
CO (1) CO2018009687A2 (fr)
CR (1) CR20180445A (fr)
DK (1) DK3430039T3 (fr)
EA (1) EA201892063A1 (fr)
FI (1) FI3430039T3 (fr)
GE (1) GEP20217232B (fr)
IL (1) IL261783B2 (fr)
LT (1) LT3430039T (fr)
MA (1) MA43773B1 (fr)
MY (1) MY195541A (fr)
PH (1) PH12018501944A1 (fr)
PT (1) PT3430039T (fr)
SA (1) SA518400022B1 (fr)
SG (1) SG11201807949WA (fr)
TN (1) TN2018000301A1 (fr)
UA (1) UA125378C2 (fr)
WO (1) WO2017158426A1 (fr)
ZA (1) ZA202003612B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3430039T3 (da) * 2016-03-14 2026-01-19 Univ I Oslo Manipulerede immunglobuliner med ændret fcrn-binding
KR102777127B1 (ko) 2016-08-02 2025-03-07 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
EP3456738B1 (fr) * 2017-09-19 2024-07-17 Tillotts Pharma Ag Variantes d'anticorps
ES2873650T3 (es) 2017-09-19 2021-11-03 Tillotts Pharma Ag Variantes de anticuerpos
WO2020114616A1 (fr) 2018-12-07 2020-06-11 Tillotts Pharma Ag Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci
EP3711772A1 (fr) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Protéines recombinantes et protéines de fusion
JP2023531141A (ja) * 2020-05-21 2023-07-21 ザイダス・ライフサイエンシーズ・リミテッド Ｆｃバリアント及びその調製
CN115572331A (zh) * 2021-07-06 2023-01-06 联邦生物科技(珠海横琴)有限公司 一种具有增强FcRn受体结合的突变子
WO2023057595A1 (fr) 2021-10-06 2023-04-13 Nordic Nanovector Asa Hh1 rew humanisé
EP4426337A1 (fr) 2021-11-05 2024-09-11 Oslo Universitetssykehus HF Constructions protéiques tandem fc d'iga et fc d'igg
WO2025014773A1 (fr) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Méthodes de traitement d'une maladie oculaire thyroïdienne chronique
WO2025221933A1 (fr) * 2024-04-17 2025-10-23 Vial Health Technology Inc. Anticorps et polypeptides comprenant des régions fc variantes

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1331443C (fr) 1987-05-29 1994-08-16 Charlotte A. Kensil Adjuvant a saponine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
CZ333796A3 (cs) 1991-03-06 1998-06-17 MERCK Patent Gesellschaft mit beschränkter Haftung Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
CA2085827C (fr) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Composition d'adjuvant contenant du lipopolycaccharide hydrophobique synthetique
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
RU2154068C2 (ru) 1993-11-17 2000-08-10 Лаборатуар Ом С.А. Глюкозаминовые дисахариды, способ их получения, фармацевтическая композиция
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
EP0930893B1 (fr) 1996-10-11 2005-04-13 The Regents of The University of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2654522C (fr) 1997-08-29 2014-01-28 Antigenics Inc. Compositions renfermant l'adjuvant qs-21 et du polysorbate ou de la cyclodextrine comme excipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (fr) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Emulsions du type huile-dans-l'eau contenant des saponines
NL1011002C2 (nl) * 1999-01-12 2000-07-20 Univ Eindhoven Tech Versterkerschakeling.
MX353234B (es) * 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU4673099A (en) 1999-02-26 2000-09-14 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
PL357448A1 (en) 2000-02-25 2004-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
ES2259030T3 (es) 2000-05-19 2006-09-16 Scancell Limited Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico.
WO2003007971A1 (fr) * 2001-07-17 2003-01-30 University Of Virginia Patent Foundation Improved heteropolymer complexes and methods for their use
JP2005508945A (ja) 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
EP2385069A3 (fr) * 2003-11-12 2012-05-30 Biogen Idec MA Inc. Variantes de polypeptides Fc se liant au récepteur (FcRn) néonatal, protéines Fc dimèriques et procédés correspondants
DK1817340T3 (da) * 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US20100098730A1 (en) * 2008-10-14 2010-04-22 Lowman Henry B Immunoglobulin variants and uses thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
AU2013251309B2 (en) * 2012-04-27 2017-06-22 Bioatla, Llc Modified antibody regions and uses thereof
CN106255704A (zh) * 2014-04-16 2016-12-21 Ucb生物制药私人有限公司 多聚体Fc蛋白
DK3430039T3 (da) * 2016-03-14 2026-01-19 Univ I Oslo Manipulerede immunglobuliner med ændret fcrn-binding

Also Published As

Publication number Publication date
JP2019518712A (ja) 2019-07-04
AU2017232546B2 (en) 2024-05-02
AU2017232546A1 (en) 2018-10-04
CN116239693A (zh) 2023-06-09
US11319383B2 (en) 2022-05-03
TN2018000301A1 (en) 2020-01-16
CL2018002639A1 (es) 2019-02-22
UA125378C2 (uk) 2022-03-02
KR20230069247A (ko) 2023-05-18
JP7155008B2 (ja) 2022-10-18
CO2018009687A2 (es) 2018-11-30
EP3430039B1 (fr) 2025-10-22
PT3430039T (pt) 2026-01-16
WO2017158426A1 (fr) 2017-09-21
MY195541A (en) 2023-01-31
JP2022188205A (ja) 2022-12-20
PH12018501944A1 (en) 2019-06-17
US20220348690A1 (en) 2022-11-03
KR20180127320A (ko) 2018-11-28
LT3430039T (lt) 2026-02-10
BR112018067897A2 (pt) 2019-04-24
SG11201807949WA (en) 2018-10-30
KR20230062894A (ko) 2023-05-09
DK3430039T3 (da) 2026-01-19
EP3430039A1 (fr) 2019-01-23
JP7636081B2 (ja) 2025-02-26
CN116789830A (zh) 2023-09-22
CA3011887A1 (fr) 2017-09-21
KR102895909B1 (ko) 2025-12-05
IL261783A (en) 2018-10-31
SA518400022B1 (ar) 2022-08-23
CA3011887C (fr) 2024-10-29
CR20180445A (es) 2019-02-08
EA201892063A1 (ru) 2019-04-30
IL261783B (en) 2022-12-01
US20190077883A1 (en) 2019-03-14
CN109071631A (zh) 2018-12-21
KR102799265B1 (ko) 2025-04-23
EP4659813A2 (fr) 2025-12-10
MA43773A (fr) 2018-11-28
CN109071631B (zh) 2023-07-14
IL261783B2 (en) 2023-04-01
ZA202003612B (en) 2022-08-31
FI3430039T3 (fi) 2026-01-12
GEP20217232B (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MA43773B1 (fr) Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
PH12018500657A1 (en) Optimized variants of anti-vegf antibodies
ZA201708265B (en) Tigit-binding agents and uses thereof
MX2019007021A (es) Anticuerpos il-11ra.
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
MA44322A (fr) Compositions comprenant des souches bactériennes
MA40671A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA42471A (fr) Compositions comprenant des souches bactériennes
MX374785B (es) Anticuerpos anti-fgfr2iiib afucosilados.
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
EA201792055A1 (ru) Антитела против cd48 и их конъюгаты
EP4603508A3 (fr) Anticorps anti-fzd et méthodes d'utilisation
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
WO2018227063A8 (fr) Anticorps anti-robo2, compositions, méthodes et utilisations
EP4467565A3 (fr) Formulations d'anticorps anti-tnf alpha
EA202192173A1 (ru) Анти-cd228 антитела и конъюгаты антитело-лекарственное средство
EA202092981A1 (ru) Антитела к l1cam и их применение
EA202091705A1 (ru) Конъюгаты пирролобензодиазепин-антитело